Type 2 Diabetes does not worsen prognosis in hepatocellular carcinoma - 05/04/11
Corresponding author. Tel.: +61 3 93427000; fax: +03-9342 7848.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 2 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Introduction |
Type 2 Diabetes (T2DM) is associated with liver inflammation and carcinogenesis. The prevalence of T2DM among patients with liver cirrhosis and hepatocellular carcinoma is increasing. However, the effect of T2DM on the natural history of hepatocellular carcinoma is not known.
Aim |
To examine the effect of T2DM on hepatocellular carcinoma (HCC) survival in treated and untreated disease.
Methods |
Retrospective analysis was performed on HCC cases diagnosed during 2000–2005, and prospectively during 2006–August2007. Demographics, HCC staging, response to treatment, and survival were collected. A comparison was made between patients with T2DM and without T2DM.
Results |
One hundred and thirty-five patients were recruited in total; 58 (43%) had T2DM. Seventy (37 diabetic) patients were treated with percutaneous radiological therapies, with 168 treatments given. Treatment was determined by AASLD guidelines and patient tolerance, there was no randomisation. There was no significant difference in survival between diabetic and nondiabetic patients. There was a nonsignificant trend towards greater survival in diabetic patients (overall median survival diabetics 21mths vs nondiabetics 5mths, P=0.355).
Conclusions |
T2DM does not negatively impact on the natural history of treated or untreated HCC.
Le texte complet de cet article est disponible en PDF.Plan
Vol 35 - N° 3
P. 214-220 - mars 2011 Retour au numéro
Article précédent
- HCV-GenoFibrotest: A combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C
- Jean-Marc Costa, Dmytro Telehin, Mona Munteanu, Tetiana Kobryn, Yen Ngo, Vincent Thibault, Moussalli Joseph, Vlad Ratziu, Yves Benhamou, Volodymyr Koz’ko, Galyna Dubins’ka, Jean-Dominique Poveda, Thierry Poynard
- A novel de novo mutation in LKB1 gene in a Chinese Peutz Jeghers syndrome patient significantly diminished p53 activity
- Lin Liu, Xiaohui Du, Jing Nie
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?